Good MorningEquity markets extended their gains on Wednesday following a better-than-expected Retail Sales figure and healthy reports from retailers Target and The TJX Companies. Both produced substantial bottom-line strength, although the causes were different. In the case of TJX Companies, sales traffic led to revenue growth and margin leverage, while Target leaned into discounts to reduce inventory. The takeaway is that consumers remain resilient if price-conscious and in search of bargains.
The S&P 500 advanced about 0.5% at the session high, but weakness started to show; by the end of the session, the market was trading near break-even. The day's candle stick formation is a small spinning top with a visible upper shadow that reveals resistance below critical levels. Because the market is overbought at current levels and trading within an established range, it will likely sell off soon without another catalyst to drive it higher. The earnings season is all but over, and there are no major economic reports due until after the Thanksgiving Holiday so another catalyst may be hard to come by. Featured: How A.I. Could Make Most 21st Century Diseases EXTINCT (Behind the Markets) 
|
Stocks | | |
Warren Buffett is widely regarded as the most well-known, famous, and successful investor of all time. As such, his investment decisions and changes to his holdings are closely monitored and highly anticipated by the investing community.
His company, financial heavyweight Berkshire Hathaway... Read the Full Story |
|
From Our Partners50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. | | | | Learn more here. |
|
Markets | | |
The world of financial markets can be a brutal jungle, filled with dangers at every turn and businesses going bankrupt or turning billionaires almost overnight. Today, some of these risks and uncertain turning points have been assessed to bring you a sensible list of companies that can be termed a... Read the Full Story |
|
Markets | | | President Joe Biden has made America's case to CEOs attending the Asia-Pacific summit in San Francisco that the United States is committed to high standards in trade that will benefit economies across the Pacific Read the Full Story |
|
From Our PartnersMaking profits in the stock market depends on making your entry at the right time. The time is NOW to get into A.I. Artificial Intelligence is turning into one of the most popular trends this year, and it has only just begun.
(**By clicking the link you are subscribing to the The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here)
| | Go HERE to Reveal Which Stock These Are |
|
Stocks | | |
The big retailers have begun to report, and news from Target (NYSE: TGT) and TJX Companies (NYSE: TJX) has their shares moving in opposite directions. Target is up nearly 15%, and The TJX Companies is down about 3% following their Q3 releases. Nevertheless, Target shares will likely hit a new low ... Read the Full Story |
|
Markets | | | Asian shares have retreated after Wall Street added a bit more to its big rally from a day before, while U.S. futures and oil prices were lower. Any lift in sentiment from a meeting between U.S. President Joe Biden and Chinese leader Xi Jinping appeared to fade after Biden, pressed by a reporter on ... Read the Full Story |
|
From Our PartnersFor investors, this may be the biggest tech opportunity you'll see in your lifetime. (HINT: It's not who you think.) | | Go HERE for details |
|
Markets | | |
Ambarella (NASDAQ: AMBA) reported some game-changing news for investors. The company was chosen to provide microchips for an automotive industry first. A start-up and joint venture between Ford Motor (NYSE: F) and ADT (NYSE: ADT) called Canopy uses the CVFlow SoC to power its aftermarket truck-bed... Read the Full Story |
|
Stocks | | |
In what’s shaping up to be another strong week for U.S. equities, traders have much to be thankful for heading into Thanksgiving week.
November 14th’s headline Consumer Price Index (CPI) reading for October came in at a cooler-than-expected 3.2%. The market cheered the result because ... Read the Full Story |
|
Markets | | | Target on Wednesday reported a hefty third-quarter profit increase that handily beat Wall Street expectations as the retailer held down costs and cut inventory. Revenue slipped more than 4%, however, as customers saddled with broadly higher costs pulled back on spending as the holiday season nears. ... Read the Full Story |
|
Markets | | | Russia's State Duma took a step forward Wednesday towards approving its biggest-ever federal budget which will increase spending by around 25% in 2024, with record amounts going on defense.Defense spending is expected to overtake social spending next year for the first time in modern Russian history... Read the Full Story |
|
Markets | | | The European Union’s executive commission has lowered growth its expectations for this year and next, saying the economy “has lost momentum” as inflation discourages consumers and higher interest rates deter borrowing for purchases and investment Read the Full Story |
|
Thursday's Early Bird Stock Of The Day First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida. | | View Today's Stock Pick |
|
